Literature DB >> 1360436

Hypersensitivity with hepatotoxicity to mesalazine after hypersensitivity to sulfasalazine.

M L Hautekeete1, N Bourgeois, P Potvin, L Duville, H Reynaert, G Devis, M Adler, G Klöppel.   

Abstract

A 21-year-old woman with Crohn's disease of the colon developed a skin rash after 3 weeks of treatment with sulfasalazine. Administration of sulfasalazine was discontinued. When mesalazine was instituted 1 week later, she developed a severe hypersensitivity reaction characterized by fever, diarrhea, skin rash with subsequent desquamation, marked atypical lymphocytosis, and severe hepatotoxicity. Recovery was complete. The clinical and biological features as well as liver pathology of this case bear a striking resemblance to earlier reports of hypersensitivity reaction with severe hepatotoxicity to sulfasalazine. The authors urge caution when mesalazine is given to a patient with known hypersensitivity to sulfasalazine.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1360436     DOI: 10.1016/0016-5085(92)91453-b

Source DB:  PubMed          Journal:  Gastroenterology        ISSN: 0016-5085            Impact factor:   22.682


  10 in total

1.  Lack of evidence for fibrosing colonopathy by 5-ASA in humans.

Authors:  M L Borum; A L Ginsberg
Journal:  Dig Dis Sci       Date:  1999-07       Impact factor: 3.199

Review 2.  Hypersensitivity to 5-ASA suppositories.

Authors:  M L Borum; A Ginsberg
Journal:  Dig Dis Sci       Date:  1997-05       Impact factor: 3.199

3.  Hyposensitization trial using salazosulfapyridine in a case of mesalamine intolerance.

Authors:  Koichi Soga; Kenji Itani
Journal:  Clin J Gastroenterol       Date:  2019-04-29

4.  An unusual cause of febrile hepatitis.

Authors:  Teresa Stelzer; Sibylle Kohler; Ewerton Marques Maggio; Ludwig Theodor Heuss
Journal:  BMJ Case Rep       Date:  2015-06-25

Review 5.  Comparative tolerability of treatments for inflammatory bowel disease.

Authors:  R B Stein; S B Hanauer
Journal:  Drug Saf       Date:  2000-11       Impact factor: 5.606

6.  Sulphasalazine and mesalazine: serious adverse reactions re-evaluated on the basis of suspected adverse reaction reports to the Committee on Safety of Medicines.

Authors:  R A J Ransford; M J S Langman
Journal:  Gut       Date:  2002-10       Impact factor: 23.059

7.  Safety and efficacy of controlled-release mesalamine for maintenance of remission in ulcerative colitis. Pentasa UC Maintenance Study Group.

Authors:  P Miner; S Hanauer; M Robinson; J Schwartz; S Arora
Journal:  Dig Dis Sci       Date:  1995-02       Impact factor: 3.199

Review 8.  Hepatic manifestations of non-steroidal inflammatory bowel disease therapy.

Authors:  Robert Hirten; Keith Sultan; Ashby Thomas; David E Bernstein
Journal:  World J Hepatol       Date:  2015-11-28

9.  Liver disorders in inflammatory bowel disease.

Authors:  Victor Uko; Suraj Thangada; Kadakkal Radhakrishnan
Journal:  Gastroenterol Res Pract       Date:  2012-02-15       Impact factor: 2.260

10.  Checkpoint Inhibition Reduces the Threshold for Drug-Specific T-Cell Priming and Increases the Incidence of Sulfasalazine Hypersensitivity.

Authors:  Sean Hammond; Anna Olsson-Brown; Sophie Grice; Andrew Gibson; Joshua Gardner; Jose Luis Castrejón-Flores; Carol Jolly; Benjamin Alexis Fisher; Neil Steven; Catherine Betts; Munir Pirmohamed; Xiaoli Meng; Dean John Naisbitt
Journal:  Toxicol Sci       Date:  2022-02-28       Impact factor: 4.849

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.